Nuvectis Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	19.46	19.13	19.99	5.74	-
Cash & Short-Term Investments	19.46	19.13	19.99	5.74	-
Cash Growth	25.83%	-4.34%	248.19%	-	-
Other Current Assets	0.25	0.06	0.41	0.09	-
Total Current Assets	19.71	19.19	20.41	5.83	-
Long-Term Deferred Charges	-	-	-	0.82	-
Total Assets	19.71	19.19	20.41	6.66	-
Accounts Payable	1.76	2.77	2.91	1.06	0.01
Accrued Expenses	3.93	4.21	2.83	0.54	-
Other Current Liabilities	-	-	0.45	0.82	-
Total Current Liabilities	5.69	6.98	6.19	2.42	0.01
Total Liabilities	5.69	6.98	6.19	2.42	0.01
Additional Paid-In Capital	72.44	66.45	46.2	1.89	-
Retained Earnings	-58.42	-54.25	-31.99	-12.9	-0.01
Total Common Equity	14.02	12.2	14.22	-11.01	-0.01
Shareholders' Equity	14.02	12.2	14.22	4.24	-0.01
Total Liabilities & Equity	19.71	19.19	20.41	6.66	-
Net Cash (Debt)	19.46	19.13	19.99	5.74	-
Net Cash Growth	25.83%	-4.34%	248.19%	-	-
Net Cash Per Share	1.22	1.23	1.58	1.35	-
Filing Date Shares Outstanding	18.36	17.77	14.75	12.72	3.9
Total Common Shares Outstanding	18.36	17.42	14.64	4.51	3.9
Working Capital	14.02	12.2	14.22	3.41	-0.01
Book Value Per Share	0.76	0.70	0.97	-2.44	-0.00
Tangible Book Value	14.02	12.2	14.22	-11.01	-0.01
Tangible Book Value Per Share	0.76	0.70	0.97	-2.44	-0.00

Source: S&P Capital IQ. Standard template.